News

Reading List

Potential Reuse of Oncology
Drugs in the Treatment of Rare Diseases

Zhichao Liu,* Hong Fang, William Slikker, and Weida Tong,*

National Center for Toxicological Research
US Food and Drug Administration
Jefferson, AR 72079
USA

*Correspondence:
Zhichao.liu@fda.hhs.gov (Z. Liu) and weida.tong@fda.hhs.gov (W. Tong).

Cancer research has made remarkable progress with the help of advancing genomics techniques, resulting in more precise clinical application and many new anticancer drugs on the market. By contrast, very few treatment options are available for rare diseases that are often progressive, severe, and life-threatening. In this opinion we elaborate on the possible association between cancers and rare diseases across three different levels including clinical observation, crosstalk between germline mutation and somatic mutation, and shared biological pathways. Consequently, by utilizing systematic drug-repositioning approaches, and taking safety issues into consideration, we suggest that oncology drugs have great potential for reuse in the treatment of rare diseases.

CellPress Trends in Pharmacological Science, October 2016, Vol. 37, Issue 10, p843-857.  Link to abstract here

~~~

Paternal Uniparental Disomy with Segmental Loss of Heterozygosity of Chromosome 11 are Hallmark Characteristics of Syndromic and Sporadic Embryonal Rhabdomyosarcoma

Abstract: Costello syndrome (CS) arises from a typically paternally derived germline mutation in the proto-oncogene HRAS, and is considered a rasopathy. CS results in failure-to-thrive, intellectual disabilities, short stature, coarse facial features, skeletal abnormalities, congenital heart disease, and a predisposition for cancer, most commonly embryonal rhabdomyosarcoma (ERMS). The goal of this study was to characterize CS ERMS at the molecular level and to determine how divergent it is from sporadic ERMS. We characterized eleven ERMS tumors from eight unrelated CS patients, carrying paternally derived HRAS c.34G>A (p.Gly12Ser; 6) or c.35G>C (p.Gly12Ala; 2) mutations. Loss of heterozygosity (LOH) was evaluated in all CS ERMS by microarray and/or short tandem repeat (STR) markers spanning the entire chromosome 11. Eight CS ERMS tumors displayed complete paternal uniparental disomy of chromosome 11 (pUPD11), whereas two displayed UPD only at 11p and a second primary ERMS tumor showed UPD limited to 11p15.5, the classical hallmark for ERMS. Three sporadic ERMS cell lines (RD, Rh36, Rh18) and eight formalin fixed paraffin embedded (FFPE) ERMS tumors were also analyzed for RAS mutations and LOH status. We found a higher than anticipated frequency of RAS mutations (HRAS or NRAS; 50%) in sporadic ERMS cell lines/tumors. Unexpectedly, complete uniparental disomy (UPD11) was observed in five specimens, while the other six showed LOH extending across the p and q arms of chromosome 11. In this study, we are able to clearly demonstrate complete UPD11 in both syndromic and sporadic ERMS.
Am J Med Genet A. Author manuscript; available in PMC 2016 Dec 1.
Published in final edited form as:
PMCID: PMC5130350
NIHMSID: NIHMS831094

~~~

In vivo severity ranking of Ras pathway mutations associated with developmental disorders

Granton A. Jindal, Yogesh Goyal, Kei Yamaya, Alan S. Futran, Iason Kountouridis, Courtney A. Balgobin, Trudi Schüpbach, Rebecca D. Burdine, Stanislav Y. Shvartsman

http://www.pnas.org/content/early/2017/01/01/1615651114.abstract

Abstract: Germ-line mutations in components of the Ras/MAPK pathway result in developmental disorders called RASopathies, affecting about 1/1,000 human births. Rapid advances in genome sequencing make it possible to identify multiple disease-related mutations, but there is currently no systematic framework for translating this information into patient-specific predictions of disease progression. As a first step toward addressing this issue, we developed a quantitative, inexpensive, and rapid framework that relies on the early zebrafish embryo to assess mutational effects on a common scale. Using this assay, we assessed 16 mutations reported in MEK1, a MAPK kinase, and provide a robust ranking of these mutations. We find that mutations found in cancer are more severe than those found in both RASopathies and cancer, which, in turn, are generally more severe than those found only in RASopathies. Moreover, this rank is conserved in other zebrafish embryonic assays and Drosophila-specific embryonic and adult assays, suggesting that our ranking reflects the intrinsic property of the mutant molecule. Furthermore, this rank is predictive of the drug dose needed to correct the defects. This assay can be readily used to test the strengths of existing and newly found mutations in MEK1 and other pathway components, providing the first step in the development of rational guidelines for patient-specific diagnostics and treatment of RASopathies.

~~~

Can a cancer drug treat a rare cardiac disease?

Yale News
 ~~~
Newsweek article 12/5/16
TRACKING DOWN ONE OF CANCER’S DEADLIEST CULPRITS, THE RAS FAMILY OF GENES*
BY JESSICA WAPNER ON 12/5/16 AT 10:30 AM
[*emphasis RASopathiesNet]

~~~

NEW PUBLICATIONS SEARCH ENGINE FORMAT: https://www.gopubmed.org

Not only does this webpage search and show abstracts, but it can also get you to the full document (either via a subscription page or the .pdf if it is available) as well as statistics, which includes top terms; top year publications; top countries; top cities; top journals; top authors; publications over time; world map; and network of top authors.

Give it a try!

[With thanks to Beth Stronach for sharing this]

~~~

 

Gelb 2016
~ Dr. Bruce Gelb ~

Stem cell breakthrough unlocks mysteries associated with inherited heart condition
Date: August 30, 2016
Source: The Mount Sinai Hospital / Mount Sinai School of Medicine

Summary:
Using advanced stem cell technology, scientists have created a model of a heart condition called hypertrophic cardiomyopathy (HCM) — an excessive thickening of the heart that is associated with a number of rare and common illnesses, some of which have a strong genetic component.
http://www.sciencedaily.com/releases/2016/08/160830212133.htm

~~~

Human Molecular Genetics Advance Access Publication Date: July 2016, Vol. 25, No. R2 R123–R132

Pathogenesis of the RASopathies

William E. Tidyman (1,3) and Katherine A. Rauen (2,3)*

1 Division of Behavioral and Developmental Pediatrics, Department of Pediatrics, 2 Department of Pediatrics, Division of Genomic Medicine, University of California Davis, Sacramento, CA, USA and 3 UC Davis MIND Institute, Sacramento, CA 95817, USA

*To whom correspondence should be addressed at: UC Davis MIND Institute, 2825 50th Street, Room 2284, Sacramento, CA 95817, USA. Tel: 916 7030204; Fax: 916 7030243; Email: rauen@ucdavis.edu

Abstract
The RASopathies are defined as a group of medical genetics syndromes that are caused by germ-line mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. Taken together, the RASopathies represent one of the most prevalent groups of malformation syndromes affecting greater than 1 in 1,000 individuals. The Ras/MAPK pathway has been well studied in the context of cancer as it plays essential roles in growth, differentiation, cell cycle, senescence and apoptosis, all of which are also critical to normal development. The consequence of germ-line dysregulation leads to phenotypic alterations of development. RASopathies can be caused by several pathogenetic mechanisms that ultimately impact or alter the normal function and regulation of the MAPK pathway. These pathogenetic mechanisms can include functional alteration of GTPases, Ras GTPase-activating proteins, Ras guanine exchange factors, kinases, scaffolding or adaptor proteins, ubiquitin ligases, phosphatases and pathway inhibitors. Although these mechanisms are diverse, the common underlying biochemical phenotype shared by all the RASopathies is Ras/MAPK pathway activation. This results in the overlapping phenotypic features among these syndromes.

doi: 10.1093/hmg/ddw191

~~~

PLoS Genet. 2016 May 19;12(5):e1006039. doi: 10.1371/journal.pgen.1006039. eCollection 2016.

The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer.

Hartung AM1, Swensen J2,3,4, Uriz IE1, Lapin M1, Kristjansdottir K1, Petersen US1, Bang JM1, Guerra B1, Andersen HS1, Dobrowolski SF3, Carey JC5, Yu P4,Vaughn C4, Calhoun A6, Larsen MR1, Dyrskjøt L7, Stevenson DA8, Andresen BS1.

Abstract

Costello syndrome (CS) may be caused by activating mutations in codon 12/13 of the HRAS proto-oncogene. HRAS p.Gly12Val mutations have the highest transforming activity, are very frequent in cancers, but very rare in CS, where they are reported to cause a severe, early lethal, phenotype. We identified an unusual, new germline p.Gly12Val mutation, c.35_36GC>TG, in a 12-year-old boy with attenuated CS. Analysis of his HRAS cDNA showed high levels of exon 2 skipping. Using wild type and mutant HRAS minigenes, we confirmed that c.35_36GC>TG results in exon 2 skipping by simultaneously disrupting the function of a critical Exonic Splicing Enhancer (ESE) and creation of an Exonic Splicing Silencer (ESS). We show that this vulnerability of HRAS exon 2 is caused by a weak 3′ splice site, which makes exon 2 inclusion dependent on binding of splicing stimulatory proteins, like SRSF2, to the critical ESE. Because the majority of cancer- and CS- causing mutations are located here, they affect splicing differently. Therefore, our results also demonstrate that the phenotype in CS and somatic cancers is not only determined by the different transforming potentials of mutant HRAS proteins, but also by the efficiency of exon 2 inclusion resulting from the different HRAS mutations. Finally, we show that a splice switching oligonucleotide (SSO) that blocks access to the critical ESE causes exon 2 skipping and halts proliferation of cancer cells. This unravels a potential for development of new anti-cancer therapies based on SSO-mediated HRAS exon 2 skipping.

~~~

J Pediatr Hematol Oncol. 2016 Jun 1. [Epub ahead of print]

Childhood Rhabdomyosarcoma in Association With a RASopathy Clinical Phenotype and Mosaic Germline SOS1 Duplication.

Salem B1, Hofherr S, Turner J, Doros L, Smpokou P.

http://www.ncbi.nlm.nih.gov/pubmed/27258033

Abstract

Childhood rhabdomyosarcoma (RMS) accounts for approximately 3.5% of cancer cases among children 0 to 14 years of age. Genetic conditions associated with high risk of childhood RMS include Li-Fraumeni syndrome, pleuropulmonary blastoma, Beckwith-Wiedemann syndrome, and some RASopathies, such as neurofibromatosis type 1, Costello syndrome (CS), and Noonan syndrome (NS). Here, we report the rare case of a 4-year-old girl with clinical features of NS who developed an embryonal RMS of the chest and needed emergent treatment. Molecular genetic testing identified a de novo, large, mosaic duplication of chromosome 2 encompassing the SOS1 gene, presumably caused by a mosaic, unbalanced translocation between chromosomes 2 and 17 found on routine cytogenetic analysis. Sequence analysis of all known genes causing Noonan spectrum disorders was negative. RMS has been reported in a few patients with NS, associated in very few with germline SOS1 mutations, but none with copy number abnormalities. This is the first report to our knowledge of early-onset RMS developing in a child with features of NS and a mosaic RAS pathway gene aberration, a large SOS1 duplication. We hypothesize that the inciting event for tumor development in this case is due to the germline mosaic duplication of SOS1, which was duplicated in all cells of the tumor, and the ultimate development of the tumor was further driven by multiple chromosomal aberrations in the tumor itself, all described as somatic events in isolated RMS tumors.

~~~

Recent advances in RASopathies

Yoko Aoki1, Tetsuya Niihori1, Shin-ichi Inoue1 and Yoichi Matsubara2

  1. 1Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan
  2. 2National Research Institute for Child Health and Development, Tokyo, Japan

Received 6 May 2015; Revised 9 August 2015; Accepted 24 August 2015

Advance online publication 8 October 2015

http://www.nature.com/jhg/journal/v61/n1/full/jhg2015114a.html

RASopathies or RAS/mitogen-activated protein kinase (MAPK) syndromes are a group of phenotypically overlapping syndromes caused by germline mutations that encode components of the RAS/MAPK signaling pathway. These disorders include neurofibromatosis type I, Legius syndrome, Noonan syndrome, Noonan syndrome with multiple lentigines (formerly called LEOPARD syndrome), Costello syndrome, cardiofaciocutaneous (CFC) syndrome, Noonan-like syndrome, hereditary gingival fibromatosis and capillary malformation–arteriovenous malformation. Recently, novel gene variants, including RIT1, RRAS, RASA2, A2ML1, SOS2 and LZTR1, have been shown to be associated with RASopathies, further expanding the disease entity. Although further analysis will be needed, these findings will help to better elucidate an understanding of the pathogenesis of these disorders and will aid in the development of potential therapeutic approaches. In this review, we summarize the novel genes that have been reported to be associated with RASopathies and highlight the cardiovascular abnormalities that may arise in affected individuals.

RASopathies Network UK News Post

Screen Shot 2016-03-10 at 10.09.54 PM

6th International Meeting on Rare Disorders of the RAS-MAPK Pathway
A workshop preceding the 2016 ESHG meeting, Barcelona

Friday, May 20, 2016, 1 pm to Saturday, May 21, 2016, 2 pm
HOTEL BARCELONA PRINCESS, Avinguda Diagonal 1, 08019 Barcelona, Spain

Organisers: Bronwyn Kerr, Marco Tartaglia, Martin Zenker

Contacts: bronwyn.kerr@cmft.nhs.ukmarco.tartaglia@opbg.net, martin.zenker@med.ovgu.de

Registration limit: 100 participants
Registration cost:
* 100 € (including buffet dinner on May 20)
* students 50 €

Fifteen years after the discovery of the first gene for Noonan syndrome, RASopathy research is relentlessly producing exciting new insights into molecular and clinical aspects of this important group of genetic disorders. Following a tradition that started in Barcelona in 2009, we announce the 6th International Meeting on Rare Disorders of the RAS-MAPK Pathway in Barcelona in May 2016. The mission of this workshop is to bring together researchers from various fields as well as clinicians and family support groups, to provide a timely update about recent achievements, to discuss and coordinate ongoing research activities, and to set milestones for improved patient management and care.

Major Topics:
• New genes, new phenotypes, and genotype phenotype correlations
• Cancer risk in RASopathies
• Mosaic RASopathies
• Molecular mechanisms
• RASopathy modeling & treatment
• RASopathy support group activities

Conference Program here

Conference Registration form here

RASopathies Case Presentation form here

~~~

Noonan Syndrome Association presents Families for Families Day
Saturday,  26 April, 2016
The Hilton Birmingham Metropole Hotel
National Exhibition Centre
Birmingham B40 1PP

Registration desk opens at 09.15 and closes by 16.00 at the latest. Speakers include  Chairman Ian Legg, Judith Van De Meerakker, Professors Bronwyn Kerr, Sahar Mansour, Jonathan Green and Michael Patton, Drs. Juan Pablo Kaski, Vin Diwaker, Shruti Garg, Pia Ostergaard.  Also Education Questions answered by Staffordshire SEND Family Partnership, and break-out group sessions.

Click here for programme
Click here for registration form

 

~~~

 

5th International Meeting on Rare Disorders of the RAS-MAPK Pathway
A workshop preceding the 2014 ESHG meeting, Milan

May 30th, 2014

Organisers: Bronwyn Kerr, Marco Tartaglia, Martin Zenker.
Contacts for enquiries or registration: bronwyn.kerr@cmft.nhs.uk, marco.tartaglia@iss.it,
martin.zenker@med.ovgu.de,

Registration limit: 100 participants
Registration cost: 50 € (dinner included)
Location: UNA Hotel Scandinavia, Via G.B. Fauché, 15 – 20154 Milan
(Metro Sempione Arona -Tram 1)

2014 Meeting on RASopathies Program

 

Steph and Daisy Nimmo (CS) are featured in an article for Rare Disease Day (28 February).  Follow this link to the article, How our daughter benefits when rare disease groups collaborate, by Stepanie Nimmo, February 19, 2014, Special Needs Jungle.

 

[more information to come]

Anahita - Helaina cropped

 

RASopathies Network USA News Post

CFC International’s New Executive Director

Hello RASopathy Cousins!

I would like to introduce all of you to Gina Peattie. She came on board with us on Jan.1 and we are teaming together until my official retirement on July 1, 2017.

Brenda Conger
Executive Director
CFC International
183 Brown Road
Vestal, NY 13850

607-772-9666
www.cfcsyndrome.org

Gina Peattie holds a Master’s Degree in Public Administration with an emphasis on Non-profit Sector Management from California State University-Northridge and a BA in Sociology from Siena College. She brings proven leadership and management skills, as well as experience working in the rare disease field to her new position of Executive Director. Gina’s most recent experience includes working at the Children’s Cardiomyopathy Foundation as the Manager of Patient Outreach & Support, overseeing all services for children diagnosed with cardiomyopathy and their families; as well as outreach and relationship building among the medical community. She has spent her career in the non-profit field and has extensive experience working with youth and families, providing counseling and support, developing programs and educational resources, training, managing volunteer programs, creating awareness initiatives and building collaborative partnerships at organizations such as the Girl Scouts of Northeastern NY, Santa Clarita Valley Youth Project, Valley Trauma Center and YWCA Bergen County Rape Crisis Center.

Gina lives in the Albany, New York area and spends her free time with her husband and two children. She is excited to get started and work with Brenda in preparation of the 2017 conference and looks forward to meeting many CFC International members in June! Gina is honored to join the CFC International team and help to advance its mission. She can be reached at gina@cfcsyndrome.org or 573-207-5105.

~~~

RASopathiesNet’s 2016 Year in Review

can be read here.

Thank you all for your past, current and future myriad contributions toward our mission!

~~~

philipstork

Congratulations to Philip Stork, MD
Oregon Health & Sciences University

Winner of the 2016
Penn Medicine Orphan Disease Center
Million Dollar Bike Ride

Team RASopathies Network Riders
Grant
Topic: Are Raf dimers targets for therapeutic intervention in RASopathies?

More information about Philip Stork here

~~~

21st Century Cures Act Passes Congress!

More information at the Bipartisan Policy Center

Wednesday, December 7, 2016

~~~

 ljosling-wfriends Interview with Leslie Josling

by Marybeth Bailey
October 30, 2016

Where are you from?
I was born in Ontario, Canada but I was raised in Vienna, Austria. I returned to Canada in my late twenties.

What do you do?
I am the Executive Director of a counselling agency in southern Ontario, Canada. The agency offers individual, couple and family therapy as well as parenting education. I am a licensed psychotherapist but I have been working in leadership positions for most of my career. My undergraduate degree is in geophysics. While I was studying that I began volunteering at a local children’s hospital and I quickly learned how much I enjoy working with people. I went back to school and pursued a graduate degree in Child Life. Many of our families with medical issues may know about Child Life, as it is a profession that works with the hospitalized child and family. I got this degree in the UK and BoIMG_2002ston, Massachusetts working with children in hospitals in four different countries. Years later I became a licensed psychotherapist (specializing in children’s mental health). I also pursued a second graduate degree in Social Innovation a few years ago. I love my work. It is immensely gratifying to have work that makes a difference in the lives of others. I also have found it curious to experience so much overlap between my chosen profession and my journey with NS. I would have never dreamt that when I studied disabling conditions in children and families that one day I might too have to face it. Ten years after being the keynote speaker for Epilepsy Ontario my oldest daughter would be diagnosed with uncontrolled seizures.

IMG_2002What are your hobbies?
I enjoy playing the guitar and singiing. I am a foodie and love to be with friends cooking and sharing meals together. I also hike and work out most days. I try to do yoga most days of the week as I find it helps me stay well.

When did you first know that you had a RASopathy?
I first learned that I had Noonan Syndrome (SOS1) at age 51 years when my oldest daughter was diagnosed (she was age 18). My oldest daughter had an extremely difficult journey with intractable (uncontrolled daily) seizures and intellectual disability. She did not present with some of the typical NS features (e.g. no heart issues and she is 5”7”) so it wasn’t obvious. It was only when genetics cast a very broad net that it came back with NS. Similarly, they didn’t think I had NS, because I am so healthy. They were extremely surprised when I tested positive.

How do you get help when you need it, and who are your supports?
First and foremost I turn to my friends and family for support. I am fortunate to have many very close friends (many of them are therapists which can be a bonus when you hit a rough patch!). I also can’t say enough about our on-line community on the RASopathies Facebook page and the Noonan Syndrome Foundation. They have provided encouragement, information and have allowed me to explore the ins and outs of the NS with others.

What bothers you most about living with Noonan’s Syndrome?
I personally have been relatively untouched by NS. My mom lost my twin during her pregnancy but I had a few health challenges. I had some feeding issues in my first four months of life, which were resolved with the introduction of soy formula. I had a VSD that resolved in childhood. Otherwise, I have enjoyed terrific health. I have not spent a single night in the hospital in 54 years. I had no learning issues and I enjoy a good level of fitness.

Two of my daughters have been more affected by NS and watching my children suffer has been the hardest part by far in living with NS. My oldest, Meghan was profoundly disabled by seizure disorder with 12-18 seizures/day which devastated her. We were fortunate that she received epilepsy surgery at age 10. The surgery, that removed 6 centimeters of brain, completely controlled the seizures and gave us a new lease on life. My youngest (17) was well and unaffected by NS until she also developed seizure disorder last year. Receiving that diagnosis in a second child just about unhinged me. It is difficult to come to terms with the effects of trauma both personally and in supporting our children.

Is there anything that you like about living with Noonan’s Syndrome?
It would be quite a stretch to say there is something I like about living with NS. Having said that, I have enjoyed meeting some wonderful people on tIMG_1643he journey and joining in sharing the distresses and delights of living with NS.
On a lighter note: I love my curly hair!

What would you tell younger children with Noonan’s Syndrome or parents
or doctors?
I have often shared my story with new parents and children as a way of offering hope. A new diagnosis often leaves parents feeling overwhelmed and terrified. There are so many things that can go wrong. Although there is much written about the variability of NS, we don’t often hear of people with NS living with the health, relationships and career that I have been privileged with. I like to remind people that really good things are possible. NS doesn’t always mean a devastating outcome.

What do you want in life and what are your dreams?
I have been so fortunate to enjoy a good, full, healthy life! I have accomplished all I could hope for with my wonderful children, my career and my amazing friendships.

~~~

Interview with Carson

(with Noonan syndrome – PTPN11)
By Marybeth Bailey
with a little help from Mom Brianna!

Carson 8 months

Where are you from?
Maynard, MA

What do you do/what grade are you in?
I am currently in daycare.

What are your hobbies?
Love to “talk” and explore everything! I am very curious. I love to sing songs, be read to and am working on trying to crawl but with not much luck, yet!

14212561_956171672290_5029880942952618252_n

When did you first know that you had a RASopathy?
We found out that I had Noonan Syndrome when I was 8 months old.

How do you get help when you need it, and who are your supports?
My parents are my biggest support system. I currently get help from early intervention for occupational therapy, physical therapy, speech pathology and a nutritionist. I also get help from my teachers at school and from my aunt and uncle who love me as if they were my second parents.

What bothers you most about living with Noonan’s Syndrome?
Nothing yet. Mom and Dad’s biggest fear is that they don’t want me to think I am different than any other kid or that I am somehow at a disadvantage for having this syndrome. Mom is also worried about how being a small male may impact my emotional wellbeing when I enter the teenage years. My mom and dad are also hoping that my undescended testes don’t impact my fertility. Overall my parent’s biggest wish for me is that I know I can do anything I set my mind to and that this Syndrome does not define me.

bae

Is there anything that you like about living with Noonan’s Syndrome?
I have met so
me really amazing people! Mom and Dad have learned who our “village” is as a result of having Noonan’s Syndrome. I have met some other amazing families dealing with similar things. They have taught all of us so many valuable lessonCarson baby bluess such as taking things day by day and appreciating the little things in life – and most importantly—to SLOW DOWN, enjoy the here and now, and to be more present.

What would you tell younger children with Noonan’s Syndrome or parents carson starsor doctors?
Parents—You will get through this. The universe only chooses the strongest parents for children with medical complications. You are stronger than you think and your baby is stronger than you think. Here is a link to Mom’s blog that she started (although she is a bit behind and needs to do another update on my heart cath J) https://lifewithcartman.wordpress.com/

carson 2

What do you want in life and what are your dreams?14039975_954728319780_6165891246391171653_n
Right now at 10-months-old my dream for life is to get everything with my health under control and live life like a “normal” 10-month-old baby. I want my parents to continue to find the strength and mental clarity to continue to come to terms and accept our new normal. I want to continue to thrive and to show others that NS does not define us.

carson surgery

14238363_957151488730_4234638518776145896_n14237518_957151254200_813010833075512211_n

~~~

DrRobertspic

Interview with Dr. Amy Roberts

What is your education history?
I pursued an undergraduate degree in biology at Swarthmore College, Swarthmore, PA.  While there I also completed my pre-med requirements and then attended Dartmouth Medical School, Hanover, NH.  After medical school I completed a residency in pediatrics at the University of Massachusetts Medical Center followed by a second three-year residency in medical genetics at Boston Children’s Hospital.How did you become a researcher?
I had done a little bit of social science research in college and some basic bench research during summer breaks but it wasn’t until my residencies that I had a chance to do clinical research.  When I was a resident in genetics I had a year of protected time to complete a research project and it was then I began a genotype phenotype correlation study and gene discovery work in Noonan syndrome that continues to this day.Why RASopathies?
I have an interest in cardiovascular genetics.  My research mentor during my residency in genetics, Raju Kucherlapati, had recently come to Harvard.  His lab sequenced chromosome 12 for the Human Genome Project and that research laid the groundwork for the discovery that mutations in the PTPN11 gene cause Noonan syndrome.  Dr. Kucherlapati is a PhD and he was very interested in understanding how particular gene mutations in PTPN11 predict medical or developmental outcomes for children with Noonan syndrome and wanted to work with an MD so we partnered to start that research study.  That was in 2002 and we now have enrolled almost 300 individuals with Noonan syndrome. I have also done some research in CFC though my main focus has been NS.What, as a researcher/doctor, interests you about rare disease?
I feel for families who are given a diagnosis that no one- not their family or friends or often even their doctors- knows anything about.  I wanted to be able to learn more and then share that knowledge to help families know as much as possible about their child’s diagnosis.How has researching RASopathies impacted and/or changed your approach to research or clinical treatment?
Research in rare disease is challenging because there are not as many people to study as there are for common disease like adult onset diabetes or high blood pressure.  One equalizer has been social media and the Internet.  Many families find me and email to be evaluated or to join my study.  And I would not have been able to complete my research without the generosity and welcoming of organizations like The Noonan Syndrome Support Group, The Noonan Syndrome Foundation, and the Rasopathies Network who have generously allowed me to post information about my studies and to recruit families I never would have had the chance to meet by only seeing patients local to the Boston area.Have you personally connected with families?  How and why is the personal connection significant for you?
This has been one of the most rewarding parts of my career.  There are now children and adults with Rasopathies that I have known for more than 10 years.  I have greatly enjoyed spending time with families at the family support group meetings and research conferences.  It gives more depth to my understanding of what it is like to live with a Rasopathy.Whom do you admire professionally? Personally?
Professionally, I admire my mentor, Raju Kucherlapati.  When we began looking for new genes that cause NS other than PTPN11, we did a lot of work without much luck and he always has the most positive attitude.  He taught me to keep trying, to stay focused, to be flexible and that the answers will come.  I have also learned so much from my colleagues in this field: Bruce Gelb, Ben Neel, Marco Tartaglia, and Maria Kontaridis just to mention a few.  Personally, I admire my parents who raised three very different, independent and successful daughters! They encouraged us to pursue what interested us most, prized education above all other achievement, and they love us unconditionally.
In Memoriam MGrund

 

bruce-gelb-md

Dr. Gelb – How did I wind up doing this anyhow?

In one of my first postings, I wrote about how I came to be a researcher studying Noonan syndrome and related disorders. But that picked up in the middle of my story as a physician-scientist. So, how did I come to do biomedical research for my life’s work?

When I was young, I very much intended to become a lawyer. I was enamored with criminal lawyers, F. Lee Bailey in particular. Perhaps the fact that he flew in for visiting day when I was at sleep-away camp to visit his son in a helicopter, landing on our ball field, impressed me. In any case, that interested changed when I was a teenager. I was fortunate enough to spend a summer in New Brunswick, NJ, participating in several social action activities (e.g., feeding impoverished senior citizens). One of the things I picked was to be a candy striper at St. Peter’s Hospital (thank goodness, there are no extant pictures of me in the garish pink and white striped coat!). By the end of the summer, I had decided to become a doctor. I stuck with that through college, taking the usual required coursework and doing well enough to qualify for a position in medical school at the University of Rochester.

While some may know early exactly what type of doctor they want to become, I wasn’t one of those. Sitting through the seemingly endless lectures during 1st and 2nd year, it dawned on me that I might like taking care of children. I spent a wonderful summer doing pediatric research before my 3rd year. By the end of pediatrics rotation as a 3rd year student, I was sure that this was my calling (I had known that I was all thumbs so the various surgical options were not appealing, but some of the other thought-based specialties like Internal Medicine and Psychiatry needed to be considered).

I headed off for my pediatric residency at Columbia still unsure of the exact kind of pediatrics I’d do. My very first rotation was with infants and children with congenital heart disease. It was so complicated but wonderfully rational (at least, it made sense to me). After finishing residency, I headed south to Houston, Texas for my clinical training in pediatric cardiology.

And how about the scientist part of things? Well, I was a really late bloomer. Although I did a few geeky scientific things growing up (chemistry set, frog dissection with my dad), no one would have picked me out as a future researcher. I did a little in college and medical school but nothing substantial nor intriguing to me. When I was in Houston, we got a new head of pediatric cardiology during my 1st year. He suggested that all of the fellows head to molecular labs for training. Most of the others blew him off, but I listened (who knows why). I was then so very fortunate to wind up in a molecular genetics laboratory with a fabulous mentor just as the Human Genome Project was taking off. Like my experience with pediatric cardiology, this stuff actually made sense to me.

From there until now, it has been, as the old saying goes, 99% perspiration and 1% inspiration. Plus, a lot of good luck and good will from others who extended a helping hand along the way. And that certainly includes my many great colleagues in the RASopathy community!

Houston

FIRST Houston-area Noonan syndrome Family Conference
Saturday, June 4, 2016
Texas Children’s Hospital – Pavilion for Women

Click HERE for schedule and registration form.  Please complete registration form and send it to Pilar Magoulas if you are able to attend.

Please contact Pilar Magoulas if there are any questions.

~~~

RASopathies Million Dollar Bike Rides and Grants information here.

~~~

 

Menendez and Max 041416

Max Schill advocates for 21st Century Cures Act

More here at NJ Senator Menendez’s site: http://www.menendez.senate.gov/news-and-events/press/menendez-meets-with-njs-max-schill-discusses-health-care-innovations

~~~

SchillStronach 2016RareDiseaseWk

Rare Disease Day 2016 at the NIH

Lisa Schill (left) and Beth Stronach (right) presented RASopathiesNetwork’s poster to raise awareness of the link between cancer and birth defects in individuals with mutations in the RAS cellular signaling pathway.

 

~~~

KontaridisYangJaffre 112515

Report on Research funded by the first University of Pennsylvania’s Orphan Disease Center Grant

Work on this project was conducted by: (left to right) Moon-Hee Yang, PhD, Postdoctoral Fellow; Fabrice Jaffre, PhD, Postdoctoral Fellow, Maria I. Kontaridis, PhD, Principal Investigator.

Delineating the cause of gastrointestinal abnormalities in RASopathy disorders using human inducible pluripotent stem cells (iPSCs)

RASopathies are a group of disorders caused by distinct mutations in genes that reside along the Ras-MAPK signaling cascade. As a result, individuals with RASopathies have unique, but similar clinical features, including gastrointestinal difficulties. This project has focused on understanding the mechanistic causes of the gastrointestinal defects in RASopathies. Using a series of reprogramming and stem cell differentiation approaches, we are working on identifying the molecular, transcriptional and epigenetic changes induced in human gastrointestinal progenitor cells as a result of these mutations.

Seed money from the UPenn RASopathies Pilot grant has been instrumental to this work, allowing us the opportunity to initiate the study and ask whether mutations in PTPN11, a RASopathy gene encoding the protein tyrosine phosphatase SHP2 and responsible for >50% of Noonan Syndrome (NS) and nearly all Noonan Syndrome with Multiple Lentigines (NSML, formally called LEOPARD Syndrome), can cause abnormalities in gut development and function. In this regard, we show here how we have successfully differentiated NSML patient-derived inducible pluripotent stem cells (iPSCs) into intestinal 3D organoids (Fig 1). The next stage of this work will compare the epigenetic and transcriptional alterations between NS and NSML-derived PTPN11 organoids using RNA-Seq and Methyl-Seq technologies. Together, these data will identify novel mechanisms underlying intestinal disease in RASopathies and will help define therapies that can target and treat these effects in patients.

SHP2^Q510E

Figure 1. Differentiation of SHP2Q510E human IPSC into intestinal 3D organoids. A. Intestinal organoids form highly convoluted epithelial structures surrounded by mesenchyme. After 21 days, the epithelium starts to form crypt-like (red arrow) and villus-like domains (black arrow) that protrude into the lumen of the 3D organoid B. Schematic representation of a 3D organoid, consisting of a central lumen lined by villus-like epithelium and several surrounding crypt-like domains. (Adapted from Sato, et al., Nature459 (7244), 262-5.2009).

 

~o~o~o~o~

 

Shvartzman RASopathies Venn 2015Shvartsman Lab published useful visuals on RASopathies phenotype/genotype relationships

This publication has a lot of valuable information about RASopathy animal models as well. Here’s a link to the publication http://www.ncbi.nlm.nih.gov/pubmed/26203125

More about Shvartsman Lab here: http://shvartsmanlab.com/

Shvartsman Lab and other labs can be found on the Researchers page.

DSCN0368DSCN0401

Congratulations to the Baileys on their 1st Annual RAS Ride June 27, 2015!

Report from Marybeth Bailey:
We raised $2000 from our 1st annual RAS ride!!  We had over 60 riders and 20 walkers.  Below is a quote from John Funk, a pretty serious cyclist from Connecticut.
“When I found out there was dirt road  ride (and walk) in Peru, VT … I said, “Yes, perfect place”.  When I dug a little deeper and learned that the ride was a charity/ awareness event for RASopathiesNET … I said, “Yes, perfect purpose”.  Riding with a REAL purpose, such as RASopathiesNET, makes the day much more meaningful … and I FELT IT that day.  It was great to see the local community come together with a purpose, ride/ walk with a purpose, and celebrate our experiences with good food/ drinks at JJ Hapgood General Store/ Eatery afterwards.  Everything about it was perfect!  I can’t wait to do it again next year!”

~~~

DrScreen Shot 2015-04-29 at 7.37.03 PM. Katherine Rauen talks about autism in the RASopathies

Read Jessica Wright’s interview with Dr. Rauen for SFARI here: http://sfari.org/news-and-opinion/q-a/2015/questions-for-katherine-rauen-cancer-pathways-autism-link

~~~

 

MKontaridis center 022115The history of how and why I started working on a very intriguing group of genetic disorders: RASopathies

by Maria Kontaridis, PhD

I have been very fortunate in my training and attribute much of my success in this field to these experiences.  Starting as a graduate student at Yale University under the mentorship of Dr. Anton Bennett, I first became aware of a class of proteins called tyrosine phosphatases.  It was there that I started working on the role of the SH2 domain-containing protein tyrosine phosphatase SHP2 in skeletal muscle differentiation.  Around this time as well, Dr. Bruce Gelb’s group at Mount Sinai identified that mutations in SHP2 contributed to the onset of human disease, and specifically, that these mutations caused approximately 50% of Noonan and nearly all of LEOPARD syndrome cases.  In addition, some of these individuals also had increased propensity for development of specific types of cancer.  Intrigued by these findings, in 2003, I joined the laboratory of Dr. Benjamin Neel at Harvard Medical School and Beth Israel Deaconess Medical Center’s division of hematology/oncology as a postdoctoral fellow, to continue work in this area.  While in Dr. Neel’s lab, we discovered that the enzymatic function of SHP2 was opposed in Noonan vs. LEOPARD syndrome-causing mutations, suggesting there was a complex causal and mechanistic role for this phosphatase in disease.

In this regard, we began to recognize that these disorders developed similar, yet very distinct, cardiac abnormalities as well.  It was this intriguing component of these disorders that I found to be most exciting, and was the critical research interest and area with which I used to launch my independent career in 2007.  Our lab developed and characterized the first LEOPARD syndrome mouse model and identified that the primary mechanism of regulation for this disorder, in contrast to Noonan syndrome and other RASopathies, was mediated through abnormal AKT/mTOR, not ERK, signaling.  In addition, we found that use of an mTOR targeted inhibitor (rapamycin) could both normalize and reverse the hypertrophic cardiomyopathy (HCM) phenotype in these mice.  Consequently, we are excited that, in collaboration with Dr. Amy Roberts at Children’s Hospital Boston and the NIH (NCATS-TRND grant support), along with collaborators Drs. Bruce Gelb, Ben Neel, and Maike Krenz, we are in process of evaluating the clinical efficacy and therapeutic potential for use of Rapalogs in treatment of HCM in LEOPARD syndrome, and perhaps other RASopathy and congenital heart disorders as well.  Our lab is continuing work in this area by trying to find ways to better understand the developmental causes and functional consequences of each of the mutations identified in RASopathies in heart and other organs and tissues.

Having attended some of the RASopathy meetings, I am humbled by the many families whose lives are touched by these disorders and whose lives we affect with our research.  As the parents and children share their stories with us, we work harder to help find ways to help make their lives easier.  I feel truly blessed to have found this research, to have opportunity to impact these children’s lives, and for the support of this amazing international community.

~~~

LSchillRare Disease Advocacy – More than Just Selling T-Shirts

by Lisa Schill

When my son was first diagnosed with a RASopathy, a rare genetic syndrome that affects cell growth and cell regulation by virtue of affecting the RAS/MAPK signaling pathway, I was so excited to finally have a diagnosis. That was quickly replaced by despair. In my hand was a handwritten note listing the next 10 specialists we needed to see. I was given no other direction on where to find accurate information about the disease, support groups, or other families who might be in similar situations. There were no t-shirts or bumper stickers to purchase so I could proudly show my support.

As a parent faced with such a daunting diagnosis, I wanted to do something to make a difference, but I really didn’t know where to start. So I started simple. I created a t-shirt to sell. My goal was to raise funds for research. Little did I know it takes over 2 BILLION dollars to create a treatment. Since then, I’ve upgraded my efforts and moved from t-shirts to bike rides. I’m working hard, in my own small way, to raise funds for RASopathies research.  But there is still so much more we can do to facilitate rare disease research.

… more here:http://www.raredr.com/contributor/isa-schill/2015/02/rare-disease-advocacy–more-than-just-selling-t-shirts

~~~

KontaridisPENN’s Orphan Disease Center Awards its RASopathies Research Grant to Dr. Maria Kontaridis

Dr. Maria Kontaridis will be conducting research on “Delineating the Cause of Gastrointestinal Abnormalities in RASopathy Disorders using Human Inducible Pluripotent Stem Cells” with the $65,000 grant.  More information at our FaceBook page: https://www.facebook.com/rasopathiesnetwork
     Funds were raised by the RASopathies Network through the 2014 Penn Million Dollar Bike Ride, and matched by Penn’s Orphan Disease Center.
     The RASopathies Network will be participating again next year.  If we raise at least $20,000, they will match up to $50,000. The bike ride will be May 9th, 2015.
     Happy New Year!!!

~~~

December 12, 2017

April Brownlee 121714

by April Brownlee

You know that spot at the very top of a roller coaster–that split second where your car is balanced perfectly at the point of the hill and your heart pounds because you know you’re about to plunge downward?

Seven years ago today.

December 12, 2007. It was afternoon. I’d heard the words “Noonan syndrome” before. But on this day, they …carried so much more weight as it became the official explanation for all we had experienced… it had already become a part of our lives. And it will always be a part of Catie’s DNA.

Many times before that day doctors told me there was no hurry to achieve a diagnosis for Catie. “What would it change?” they asked. “Nothing,” they would tell me, answering their own question. Over and over, I was told it wasn’t worth pursuing a diagnosis because it would be complicated and it wouldn’t change Catie’s treatment plan. We would just manage symptoms, they’d say, no matter what the cause.

But that diagnosis changed everything. Noonan syndrome isn’t WHO Catie is. But it’s a HUGE part of who she is. Noonan syndrome is part of how she looks, how she grows, how she develops, how she acts, how she moves, what she can and can’t eat. No, it’s not who she is. But it’s a part of every part of her.

When Catie was three, I began having gentle conversations with her about her diagnosis. I stole our quiet moments in the car when it was just the two of us and carefully broached the subject. I was so grateful I had a name to give it. I can’t imagine telling a child–or anyone, really-they’re experiencing such chaos and nobody knows why.

Knowing what is responsible for all that Catie experiences also makes ME feel better. It may sound selfish to you. After all, I don’t have to live with a syndrome. But I did have to fight for that diagnosis. I stayed up all hours of the night researching symptoms. I lumbered at the back of a room, restraining my ownself, while various people in scrubs strapped my screaming baby to a cold, hard board to conduct x-rays and various other imaging. I routinely counted her respirations at 2 a.m., decisively armed with a number that would gauge for me at what point we should head to the emergency room. And when that time came, so many nights, I carried her into the ER while her dad stayed home with our older child. I sat there, alone, whispering in her ear, “You can count on me.” I gave myself a pep talk in her hospital room in the middle of the night as I battled through a fever, shivering uncontrollably, still somehow coaxing myself into enough coherence to assist in her round the clock breathing treatments. So, yes, I wanted a diagnosis. Probably more than anyone. I just needed to know.

And now I do.

Then I guess we began the descent to the bottom. Everyday since that day has felt so much less weighted than all the days before.

These days, from time to time, when something about herself seems curious to her, a very sassy 8-year-old Catie cocks her hip to one side, sticks out a leg, tosses her massively curly hair and asks me, “Is that ’cause I have syndrome?”

“Yes,” I answer, choking back a snicker and some tears. “It’s because you have syndrome. Noonan syndrome.”

 

~~~

 

Congressman Lance

 

 

 

 

 

Lisa Schill is quoted in news article about Congressman Leonard Lance continuing as Republican Chair of Congressional Rare Disease Caucus – December 10, 2014

–Read more here: http://www.nj.com/hunterdon-county-democrat/index.ssf/2014/12/congressman_leonard_lance_will_1.html

 

~~~

News stories about Alcino Silva’s discovery: Statins Reported to Reverse Learning Disabilities – http://www.examiner.com/article/statins-reported-to-reverse-learning-disabilities
and http://www.sciencedaily.com/releases/2014/11/141110124235.htm

From the UCLA Office of Intellectual Property & Industry-Sponsored Research: http://techtransfer.universityofcalifornia.edu/NCD/20191.html

In search for a cure for NF1 and Noonan: unexpected turns and lucky breaks!
by Alcino J Silva, UCLA

When I was a graduate student in Ray White’s laboratory, where the first Rasopathy gene (NF1) was cloned in 1990, I learned from David Viskochil, then a post-doc in Ray’s lab, that NF1 subjects had an unusual high rate of cognitive deficits. I will never forget David’s words: “When you have your memory lab, remember to study NF1”. His words implied a confidence in my future that frankly surprised me, and I never forgot his advice. After my Ph.D., I went to Susumu Tonegawa’s lab at MIT, where I helped to bring mouse genetic approaches to studies of learning and memory. At MIT I got to know Tyler Jacks, a post-doctoral fellow in Robert Weinberger’s lab. Tyler derived mice with a mutation in the NF1 gene, and I immediately asked him for a collaboration. When I set up my own research group at Cold Spring Harbor Labs, one of our first projects was to test whether the NF1 mice that Tyler made at MIT had learning deficits related to the deficits that David Viskochil had described to me many years earlier.

Our studies of the learning deficits of NF1 mutant mice uncovered a mechanism and a treatment for this condition. Rui Costa and Yijun Cui in the laboratory found that the mutation of this gene in mice leads to abnormally high synaptic inhibition that results in deficits in plasticity mechanisms used for learning. I will never forget the excitement in the laboratory when Steve Kushner and Weidong Li discovered a treatment for the learning deficits in NF1 mice! Remarkably, they found that an FDA approved drug (lovastatin), that decreases Ras signaling, reverses the behavioral and physiological deficits of the NF1 mutant mice. A project that started as a quixotic far fetched dream, had actually resulted in what many assumed to be impossible: an adult treatment for a condition that we all knew affected brain development! Fortunately, other scientists shared our excitement for this discovery, and within a few years there were several clinical trials started to test the treatment we had discovered. The results so far are encouraging: a number of published experiments with lovastatin seem to confirm our findings in mice, and we are anxiously waiting for the results of a large lovastatin Army-funded clinical trial.

Following our work with NF1, it was natural for us to study another RASopathy. Like NF1, many Noonan syndrome subjects also experience learning and memory difficulties as well as other psychiatric and neurological symptoms. Therefore, Yong-Seok Lee and Dan Ehninger in the laboratory used Noonan mutant mice that Benjamin Neel’s lab had derived, to discover the brain mechanism and a treatment for this Rasopathy. Since the behavioral deficits of Noonan and NF1 subjects are similar, and since both conditions are caused by high Ras signaling, we assumed that the mechanisms of these two conditions would be very similar. This was a reasonable assumption, but nature has a way of surprising us! We were astonished to find that unlike NF1, synaptic inhibition was completely normal in the Noonan mice! After much searching and many late nights, we found that the problem in Noonan is excitatory synaptic transmission! In the Noonan mice, the excitatory synaptic increases needed for learning are prevented by exuberant Ras signaling that saturates excitatory synaptic function!

The synaptic saturation hypothesis was reasonable, but it needed to be tested directly, since the cognitive impairments could have been caused by disruptions in brain development. This was more than a conjecture, since the Neel Lab had actually demonstrated developmental deficits in these mice. So, Yong-Seok Lee in the lab engineered viruses that could deliver a Noonan mutation to specific cells in the adult brain. His results were nothing short of amazing: he was able to recreate the physiological and behavioral deficits he had described for Neel’s mice, and in his experiments developmental problems could not explain the behavioral deficits! More importantly, Yong-Seok’s data suggested that since we could reconstruct the deficits he discovered by introducing the mutation in adult mice, we may also reverse the effects of the mutation in adults and one day help the many millions of patients with Noonan syndrome!

Emboldened by these findings, Yong-Seok next tried to reverse the learning deficits of Noonan mice with the same FDA drug that was successful in NF1 (both conditions are caused by high Ras signaling, and lovastatin reverses these increases). His results were extremely encouraging: a brief treatment with lovastatin was able to reverse the learning deficits in the Noonan mice even when the treatment was started in adults!

Of course, we cannot be sure that the treatment we developed in mice (to be published in Nature Neuroscience on November 10, 2014) will be successful in clinical trials. The road from mouse models to clinical treatments is long and fraught with many pitfalls. Even if our treatment works in a significant number of Noonan subjects, there are no guarantees that we will be able to demonstrate overall clinical improvement. The psychological tests commonly used to determine the effects of drugs on cognition are very blunt and may fail to detect the improvements in patients. There is also significant genetic variability amongst Noonan patients that may confound the results of the trial. It is a sad fact that all commonly used neurological and psychiatric treatments only work in a fraction of patients they were intended to help. Additionally, even if our treatment reverses the biochemical deficits caused by Noonan mutations, it may take sometime before patients and their families can see clear quality of life improvements. Even after the biochemical deficits are corrected, patients will have to catch up with all that they missed while growing up…

However, there is reason for hope! It was not long ago that many scientists thought that what we have done was impossible! In science, the impossible today is tomorrow’s breakthrough. At every step of the way, the ingenuity and hard work of the exceptional young scientists I have had the privilege to work with, have found ways to make the improbable, even the impossible, not only probable but also real! I remember countless times when their resolve was strengthened by conversations with NF1 and Noonan families, and by the realization that the future of the children they met depended on the work they were doing in the lab. It is their enthusiasm and determination, their irrepressible idealism, dedication and hard work that convinces me that one day in the not too distant future, we WILL have treatments for all RASopathies!

 

~~~

Katherine Rauen named 2014 Rare Champion of Hope honoree at 2014 Global Genes Summit

(UC Davis Health System Newsletter, SACRAMENTO, Calif.) —

rauen_katherine200

Katherine Rauen

Katherine Rauen, professor in the Department of Pediatrics and a physician-scientist affiliated with UC Davis MIND Institute and UC Davis Children’s Hospital, has been announced as the 2014 Rare Champion of Hope Honoree in Science. The honor, awarded by the Global Genes Project, recognizes her unwavering commitment to rare disease, her investment in new treatments and her care and respect for patients.

The award will be presented at the Global Genes Project’s Tribute to Champions of Hope Gala awards ceremony on Saturday, Sept. 13 at the Hyatt Regency in Huntington Beach, Calif.

~~~

On Saturday, May 3, 2014,  Lisa Schill and the team she pulled together participated in the University of Pennsylvania’s new Center of Orphan Drug Research and Therapy to raise over $30,000, which CODRT will match 1:1 to fund research on the RASopathies.
Words from Lisa on Sunday, the day after the race:
When Max was diagnosed, I felt so alone. A doctor introduced Kelly Hudak and I via email since our sons were diagnosed with the same rare disease. That was 3 years ago. Her son just went through open heart surgery. My son was about to have spinal surgery. We have stayed in touch with each other via Facebook, we have never met in person. We met each other for the first time yesterday. Our children were able to meet yesterday. Both of us don’t have a lot of biking experience but decided to do the 77 miles together. It took us 7hrs and 23 minutes. I wouldn’t have been able to get through it without her and all those affected with the syndromes who sometimes go through so much more. I wouldn’t have been able to through it without my team, some who I knew and others who I did not but all were willing to lend a hand and help. The Million Dollar Bike Ride raised 1.4 Million Dollars for Rare disease. Our team raised over $30,000 that will be matched to create a RASopathies research grant. I will remember this day for the rest of my life. It is an experience that will always fill my heart with joy. Thank you to all who contributed. Thank you for taking the time to care. I am forever grateful.
xoxo – Lisa Schill Team Captain of the RASopathies Network Team

2014 CODRT fundraiser - Matt

[Matt cheering along the route]

Kelly and Lisa

[Kelly Hudak and Lisa Schill at the finish line.]

Steph Nimmo’s story about Daisy (with Costello syndrome) is featured on Global Genes, “How Our Daughter Benefits When Rare Disease Groups Collaborate” – Thank you Steph!

Lisa Schill represented RASopathiesNet at the New Jersey Rare Disease Day event at the New Jersey State House March 13, 2014.

Katherine Rauen receives Presidential Early Career Award for Scientists and Engineers
Go here for White House Announcement

UCSF RASopathies Research Program Newsletter ~ January 2014